PharmaLex Group expandsto the Nordic Region by merging with Lindeq AS


Friedrichsdorf (Ts.) / Mannheim / Oslo, March 23rd 2016: The PharmaLex Group announces the merger with Lindeq AS (Norway) to further strengthen and support the growing local and international customer base in the Nordic Region. PharmaLex reaches another key milestone to drive internationalization aiming for "Global Reach with Local Presence". This merger is in line with the internationalization objective of the PharmaLex Group, which included the opening of a Swiss affiliate in January 2016.


Lindeq AS was founded in 2004 and is a medical consultancy specialized in drug safety and pharmacovigilance, cosmetovigilance, quality management and medical device vigilance. The services offered cover the entire product lifecycle - pre and post product launch. The company is based in Oslo, Norway, with affiliates in Copenhagen, Denmark and Sofia, Bulgaria. Lindeq AS employs 21 people from various backgrounds.


"It was a logical step for Lindeq's further evolvement to join the PharmaLex Group" says dr. Steen Lindequist, founder and chairman of the board. "We are excited by the idea of building a new world-class champion in the area of scientific services, regulatory affairs and pharmacovigilance" says Solveig Blomvik, co-founder and CEO of Lindeq AS.  "We are very happy, that we found Lindeq AS, having the same mindset and pursuing the same goal of internationalization to provide global presence with local reach to our customers" details Dr. Thomas Dobmeyer, CEO PharmaLex. "In today's increasingly complex healthcare market, it is a key value objective to offer high flexibility and broad experience. With Lindeq AS, we have found the ideal experts to expand our service portfolio to the Nordic region" added Dr. Tilo Netzer, CEO PharmaLex.  


The PharmaLex Group now has over 450 employees, with 16 offices in 12 countries and more than 500 satisfied clients worldwide.



About PharmaLex <Confidence beyond compliance>:

PharmaLex combines local expertise with global reach in the area of scientific services, regulatory affairs and pharmacovigilance. A proven track record of success in outsourcing programs with more than25,000 successfully completed projects for over 500 clients worldwide as well asextensive experience in all therapeutic areas and product groups including advanced therapy medicinal products and biopharmaceuticals, medical and borderline products and alternative therapeutic approaches.


For further information please contact:

Ms. Deniz Oppolzer
PharmaLex GmbH; Vice President Business Development
+49 152 01 58 73 18
Harrlachweg 6
68163 Mannheim